Becton, Dickinson and Company develops medical technologies used in medication delivery, diagnostics, laboratory automation, and clinical care. Its products include syringes, needles, infusion systems, specimen collection devices, microbiology instruments, and bioscience research tools. Revenue comes from healthcare institutions, laboratories, and research customers purchasing capital equipment and repeat-use medical consumables.
Becton Dickinson & Co. (BDX) has a MarketKingdoms composite score of 64.3 (B), an B-range rating. It ranks 896th of 1,866 covered companies, 41st of 78 in Healthcare (sector average 64.5) and 4th of 9 in Medical Instruments & Supplies. Scores as of 2026-10-25.
Its strongest lenses are Industry opportunity at 82 (Healthcare average 81) and Trend (momentum) at 77 (Healthcare average 50). Its weakest lenses are Expansion (growth) at 26 (sector average 50) and Quality (profitability) at 32 (sector average 50).
| Lens | Type | BDX | Healthcare average | Medical Instruments & Supplies average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 82 | 81 | 82 | 77th |
| Stock selection | Research signal | 74 | 79 | 78 | 23rd |
| KPI momentum | Research signal | 62 | 78 | 76 | 16th |
| Catalyst watch | Research signal | 76 | 74 | 76 | 64th |
| Price (valuation) | Fundamental lens | 60 | 50 | 49 | 67th |
| Expansion (growth) | Fundamental lens | 26 | 50 | 45 | 12th |
| Quality (profitability) | Fundamental lens | 32 | 50 | 46 | 22nd |
| Trend (momentum) | Fundamental lens | 77 | 50 | 36 | 87th |
The most recent call analysed was held on 2026-08-06 (fiscal 2026 Q3). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -4.6%: its price is in line with the path its market, sector and industry moves explain. Factor sensitivity: market beta 0.82, sector beta 0.69, industry beta 0.30; the factor model explains 44% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| ResMed Inc. (RMD) | 67.4 | B | +6.1% |
| Intuitive Surgical Inc. (ISRG) | 66.2 | B | -11.5% |
| West Pharmaceutical Services Inc. (WST) | 65.1 | B | -25.9% |
| Baxter International Inc. (BAX) | 61.6 | B- | -0.9% |
| Alcon Inc. (ALC) | 61.0 | B- | -14.7% |
| Align Technology Inc. (ALGN) | 60.0 | B- | -17.5% |
| The Cooper Companies Inc. (COO) | 56.7 | C+ | -20.6% |
| Medline Inc. (MDLN) | 53.7 | C+ | -12.2% |
Becton Dickinson & Co. financial statements · Healthcare sector ranking · Medical Instruments & Supplies industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.